Joery den Hoed

Dr. Joery den Hoed

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
JHJoery den Hoed
Joery den Hoed
KDKarthikeyan Devaraju
Karthikeyan Devaraju
SFSimon E Fisher
Simon E Fisher
The discovery of the FOXP2 transcription factor, and its implication in a rare severe human speech and language disorder, has led to two decades of empirical studies focused on uncovering its roles in the brain using a range of in vitro and in vivo methods. Here, we discuss what we have learned about the regulation of FOXP2 , its downstream effectors, and its modes of action as a transcription factor in brain development and function, providing an integrated overview of what is currently known about the critical molecular networks.

7 August 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ADAlexander J. M. Dingemans
Alexander J. M. Dingemans
MHMax Hinne
Max Hinne
KTKim M. G. Truijen
Kim M. G. Truijen
LGLia Goltstein
Lia Goltstein
JRJeroen van Reeuwijk
Jeroen van Reeuwijk
BVBert B. A. de Vries
Bert B. A. de Vries

1 December 2020 in Current Opinion in Genetics & Development
Verified
Journal Article
Open access
JHJoery den Hoed
Joery den Hoed
SFSimon E Fisher
Simon E Fisher
Rare genetic variants that disrupt speech development provide entry points for deciphering the neurobiological foundations of key human capacities. The value of this approach is illustrated by FOXP2, a transcription factor gene that was implicated in speech apraxia, and subsequently investigated using human cell-based systems and animal models. Advances in next-generation sequencing, coupled to de novo paradigms, facilitated discovery of etiological variants in additional genes in speech disorder cohorts. As for other neurodevelopmental syndromes, gene-driven studies show blurring of boundaries between diagnostic categories, with some risk genes shared across speech disorders, intellectual disability and autism. Convergent evidence hints at involvement of regulatory genes co-expressed in early human brain development, suggesting that etiological pathways could be amenable for investigation in emerging neural models such as cerebral organoids.

24 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJoery den Hoed
Joery den Hoed
ESElliot Sollis
Elliot Sollis
HVHanka Venselaar
Hanka Venselaar
SESara B. Estruch
Sara B. Estruch
PDPelagia Deriziotis
Pelagia Deriziotis
SFSimon E. Fisher
Simon E. Fisher
Recurrent de novo variants in the TBR1 transcription factor are implicated in the etiology of sporadic autism spectrum disorders (ASD). Disruptions include missense variants located in the T-box DNA-binding domain and previous work has demonstrated that they disrupt TBR1 protein function. Recent screens of thousands of simplex families with sporadic ASD cases uncovered additional T-box variants in TBR1 but their etiological relevance is unclear. We performed detailed functional analyses of de novo missense TBR1 variants found in the T-box of ASD cases, assessing many aspects of protein function, including subcellular localization, transcriptional activity and protein-interactions. Only two of the three tested variants severely disrupted TBR1 protein function, despite in silico predictions that all would be deleterious. Furthermore, we characterized a putative interaction with BCL11A, a transcription factor that was recently implicated in a neurodevelopmental syndrome involving developmental delay and language deficits. Our findings enhance understanding of molecular functions of TBR1, as well as highlighting the importance of functional testing of variants that emerge from next-generation sequencing, to decipher their contributions to neurodevelopmental disorders like ASD.

21 October 2019 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Open access
ATAmanda K. Tilot
Amanda K. Tilot
AVArianna Vino
Arianna Vino
KKKaterina S. Kucera
Katerina S. Kucera
DCDuncan A. Carmichael
Duncan A. Carmichael
LHLoes van Den Heuvel
Loes van Den Heuvel
SFSimon E. Fisher
Simon E. Fisher
Synaesthesia is a neurological phenomenon affecting perception, where triggering stimuli (e.g. letters and numbers) elicit unusual secondary sensory experiences (e.g. colours). Family-based studies point to a role for genetic factors in the development of this trait. However, the contributions of common genomic variation to synaesthesia have not yet been investigated. Here, we present the SynGenes cohort, the largest genotyped collection of unrelated people with grapheme–colour synaesthesia ( n = 723). Synaesthesia has been associated with a range of other neuropsychological traits, including enhanced memory and mental imagery, as well as greater sensory sensitivity. Motivated by the prior literature on putative trait overlaps, we investigated polygenic scores derived from published genome-wide scans of schizophrenia and autism spectrum disorder (ASD), comparing our SynGenes cohort to 2181 non-synaesthetic controls. We found a very slight association between schizophrenia polygenic scores and synaesthesia (Nagelkerke's R 2 = 0.0047, empirical p = 0.0027) and no significant association for scores related to ASD (Nagelkerke's R 2 = 0.00092, empirical p = 0.54) or body mass index ( R 2 = 0.00058, empirical p = 0.60), included as a negative control. As sample sizes for studying common genomic variation continue to increase, genetic investigations of the kind reported here may yield novel insights into the shared biology between synaesthesia and other traits, to complement findings from neuropsychology and brain imaging. This article is part of a discussion meeting issue ‘Bridging senses: novel insights from synaesthesia'.

29 December 2022 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ESElliot Sollis
Elliot Sollis
JHJoery den Hoed
Joery den Hoed
MQMarti Quevedo
Marti Quevedo
SESara B Estruch
Sara B Estruch
AVArianna Vino
Arianna Vino
SFSimon E Fisher
Simon E Fisher
TBR1 is a neuron-specific transcription factor involved in brain development and implicated in a neurodevelopmental disorder (NDD) combining features of autism spectrum disorder (ASD), intellectual disability (ID) and speech delay. TBR1 has been previously shown to interact with a small number of transcription factors and co-factors also involved in NDDs (including CASK, FOXP1/2/4 and BCL11A), suggesting that the wider TBR1 interactome may have a significant bearing on normal and abnormal brain development. Here, we have identified approximately 250 putative TBR1-interaction partners by affinity purification coupled to mass spectrometry. As well as known TBR1-interactors such as CASK, the identified partners include transcription factors and chromatin modifiers, along with ASD- and ID-related proteins. Five interaction candidates were independently validated using bioluminescence resonance energy transfer assays. We went on to test the interaction of these candidates with TBR1 protein variants implicated in cases of NDD. The assays uncovered disturbed interactions for NDD-associated variants and identified two distinct protein-binding domains of TBR1 that have essential roles in protein–protein interaction.